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Abstract
Background: Hemodialysis (HD) patients who are resistant to erythropoiesis-stimulating agents (ESAs) have a
higher mortality rate. The aim of this study was to assess the relationship between the time-dependent variability of
ESA response in HD patients and mortality.
Methods: A total of 375 HD patients were enrolled in this study. The ESA resistance index (ERI) was calculated by
dividing the weekly weight-adjusted ESA dose by hemoglobin concentration, and the average ERI was calculated
from the ERI values every 2 months during a 36-month follow-up period. We divided the patients into six groups
based on the patterns of their ERI level fluctuations: low-low (Low group), intermediate-intermediate (Intermediate
group), high-high (High group), Low-intermediate group, Intermediate-high group, and Low-high group.
Results: There were 94 (25.1 %) deaths, and they included 51 (13.6 %) deaths from cardiovascular disease (CVD).
A multivariate analysis with adjustment for age, serum albumin and C-reactive protein levels, and history of CVD
showed that the High group was independently and significantly related to all-cause mortality (odds ratio = 5.53,
95 % CI 2.29–13.99, p = 0.0001) and CVD-related mortality (odds ratio = 3.49, 95 % CI 1.40–8.47, p = 0.0081).
Conclusions: High ERI levels are an independent risk factor for all-cause and CVD mortality in HD patients.
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Background
Renal anemia in end-stage renal disease (ESRD) patients
is mainly attributable to decreased erythropoietin pro-
duction by the kidney. Erythropoiesis-stimulating agent
(ESA) therapy has resulted in substantial health benefits
for ESRD patients, including improved quality of life, a
reduced need for blood transfusion, and greater exercise
capacity [1]. Unfortunately, a considerable proportion of
ESRD patients exhibit a suboptimal hematologic re-
sponse to ESAs, as evidenced by persistence of the
anemia despite adequate dosing or by the need for high-
dose ESA therapy to achieve the recommended
hemoglobin target [2].
After making adjustments for other variables, previous
studies have shown that the need for ESA therapy is an in-
dependent predictor of all-cause mortality in HD patients
[3]. Lopez-Gomez et al. reported finding a relationship be-
tween ESA resistance in HD patients and 1-year mortality
[4], and ESA resistance remained a significant predictor of
mortality in HD patients [5, 6]. It appears that resistance
to ESA therapy in HD patients could be clinically useful
as an index of prognostic marker.
However, the time-dependent changes of ESA resist-
ance index (ERI) has not examined, although consist-
ently high ESA resistance was expected to be an adverse
effect on mortality of HD patients. The aim of our study
was to assess the presence of variability in the time
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values and increased mortality of HD patients.
Methods
Subjects and protocol
This was a prospective, observational cohort study con-
ducted at a single center in Japan. The subjects were re-
cruited from among patients who had been routinely
treated through an arteriovenous fistula in the dialysis
unit of the Jyoban Hospital for at least 6 months. A total
of 400 HD patients were registered in this study, and the
375 patients for whom sufficient data were available to
calculate ERI were the subjects of the analysis in this
study. The Institutional Review Board of the Jyoban Hos-
pital approved all study protocols (No. 12), and the proto-
cols were carried out in accordance with the Declaration
of Helsinki guidelines regarding ethical principles for
medical research involving human subjects. Written in-
formed consent was obtained from every subject.
Baseline data at the time of patient entry into the study
were collected on demographics, medical history, labora-
tory data, anemia therapy, medications, and history of car-
diovascular disease (CVD). Data were collected at 2-
month intervals on events, including all-cause deaths, and
on CVD mortality. A CVD death was defined as a death
that was attributed to acute myocardial infarction, ische-
mic heart disease, cardiac arrest, congestive heart failure,
pulmonary edema due to exogenous fluid, cardiac
arrhythmia, cerebrovascular accident, including intracra-
nial hemorrhage or ischemic brain damage, and peripheral
artery disease. The patients who were enrolled as subjects
(n = 375) underwent stable regular HD with a bicarbonate
dialysate. Their underlying diseases of ESRD were diabetic
nephropathy (n = 162), chronic glomerulonephritis (n =
123), nephrosclerosis (n = 78), and chronic pyelonephritis
(n = 4), or unknown origin (n = 8).Fig. 1 Definition of variability in the time course of ERISubjects’ anemia was treated according to the guidelines
published in 2008 by the Japanese Society of Dialysis Ther-
apy [7]. The target Hb level was 10–11 g/dl, and epoetin
beta was administered to achieve the target Hb level. Intra-
venous iron was administered whenever a subject’s trans-
ferrin saturation was found to be <20 % or the serum
ferritin level was found to be <100 ng/ml. The conversion
ratio adopted in this study was 200 epoetin (EPO):1
darbepoetin-α (DA) [8]. ERI was calculated as the weekly
weight-adjusted dose of ESA divided by hemoglobin (Hb)
concentration used to evaluate the dose-response effect in
ESA treatment as follows [5, 6]: ERI (U/kg/week/g per
100 ml) = weekly ESA dose / (weight ×Hb). Ascending
quartiles of ERI were assessed based on the ERI levels at
enrollment, and the ERI quartile groups were as follows:
first, <5.1; second, 5.1 to <8.5; third, 8.5 to <13.7; and
fourth, ≥ 13.7 U/kg/week/g per 100 ml. The definition of
variability in the time course of ERI is shown in Fig. 1. ERI
levels were categorized as low (first quartile of ERI), inter-
mediate (second and third quartiles of ERI), and high
(fourth quartile of ERI). The average ERI was calculated
from ERI levels every 2 months during the follow-up period
for each patient. To assess the size of the ERI fluctuations
during the follow-up periods according to ERI quartiles at
baseline, we divided the patients into six groups on the
basis of their overall fluctuation pattern with reference to a
previous report on Hb fluctuations and mortality [9]: low-
low (Low group), intermediate-intermediate (Intermediate
group), high-high (High group), Low-intermediate group,
Intermediate-high group, and Low-high group, and the last
three groups were treated as amplitude fluctuation groups.
Statistical analyses
All data are reported as means ± SD unless otherwise
specified. The differences between groups were tested
for statistical significance by Student’s t test or one-way
Table 1 Baseline characteristics of the study subjects
Total (n = 375) Male (n = 242) Female (n = 133)
Age, years 66.8 ± 13.6 64.6 ± 13.6 70.5 ± 12.2
BMI, kg/m2 22.0 ± 3.5 22.3 ± 3.4 21.5 ± 3.7
HD vintage, months 65.3 ± 75.2 58.7 ± 69.1 77.6 ± 84.3
Single-pool Kt/V 1.4 ± 0.3 1.3 ± 0.2 1.6 ± 0.3
Hb, g/dl 10.8 ± 1.1 10.8 ± 1.1 10.7 ± 1.0
Ferritin, ng/ml 89.6 ± 86.7 84.7 ± 87.9 97.0 ± 82.7
Albumin, g/dl 3.6 ± 0.3 3.7 ± 0.4 3.6 ± 0.3
CRP, mg/dl 0.6 ± 1.5 0.6 ± 1.4 0.6 ± 1.8
Intact PTH, pg/ml 152.1 ± 164.7 146.9 ± 157.1 162.1 ± 178.8
Phosphorus, mg/dl 5.3 ± 1.3 5.3 ± 1.4 5.2 ± 1.2
Calcium, mg/dl 8.7 ± 0.7 8.6 ± 0.8 8.7 ± 0.6
ALP, U/l 245.4 ± 99.4 231.9 ± 84.7 268.3 ± 117.3
TSAT, % 21.9 ± 11.3 22.8 ± 11.9 20.1 ± 9.9
Systolic BP, mmHg 149.6 ± 22.5 150.5 ± 22.8 148.2 ± 22.0
Diastolic BP, mmHg 78.0 ± 13.9 79.5 ± 14.5 75.4 ± 12.5
History of CVD 11.2 % 12.4 % 8.3 %
ESA dosage, IU/week 5444 ± 3538 5473 ± 3700 5392 ± 3238.6
ERI, IU/kg/week/g/dl 10.5 ± 7.8 9.6 ± 7.3 12.1 ± 8.4
All data are presented as mean ± SD
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categorical variables. First, we evaluated the associations
between the six ERI variation groups and cumulative all-
cause and CVD-related mortality during the follow-up
period by the Kaplan-Meier method. Next, we estimated
the odds ratios (ORs) of all-cause and CVD-related mor-
tality according to the ERI variability groups by the lo-
gistic regression. Logistic regression was also used to
assess associations between patient characteristics and
all-cause and CVD-related mortality. The candidates for
explanatory variables were age, sex, dialysis vintage, body
mass index (BMI), the presence of diabetes, mean serum
albumin (≥3.5 vs. <3.5 g/dl), mean C-reactive protein
(CRP ≥ 1.0 vs. <1.0 mg/dl), ferritin (≥100 vs. <100 ng/
ml), phosphorus (≥6 vs. <6 mg/dl), and history of CVD
(yes vs. no or missing). All significant variables in the
univariate analysis (p < 0.20) and clinically established fac-
tors were entered into an intermediate multivariate logis-
tic model of mortality, and all of the significant variables
detected in the intermediate multivariate model and the
established factors were entered into a final multivariate
logistic mortality model. Statistical significance was de-
fined as p < 0.05. All analyses were performed using the
SAS version 9.1 (SAS Institute, Cary, NC, USA).BMI body mass index, Hb hemoglobin, CRP C-reactive protein, PTH parathyroid
hormone, ALP alkaline phosphatase, TSAT transferrin saturation, BP blood pressure,
CVD cardiovascular disease, ERI ESA resistance indexResults
The data of a total of 375 Japanese HD patients were an-
alyzed, and their mean follow-up period was 31.3 ±
9.4 weeks. Patient characteristics at baseline are summa-
rized in Table 1. The mean ESA doses during the follow-
up period calculated in the form of EPO doses were
5444 ± 3538 IU/week in all patients, 5473 ± 3700 IU/
week in males, and 5392 ± 3239 IU/week in females.
One hundred sixty-three patients were treated with
EPO, whereas 212 patients were treated with DA dur-
ing the follow-up period. The ERI distribution pattern
did not appear to differ between the sexes, but the
average ERI was significantly higher in females than
in males (12.1 ± 8.4 vs. 9.6 ± 7.3 U/kg/week/g per
100 ml, p < 0.001).
The patients were divided into the following six ERI
variability groups based on their ERI quartiles levels:
High group, n = 31 (8.3 %); Intermediate group, n = 68
(18.1 %); Low group, n = 46 (12.3 %); Intermediate-high
group, n = 30 (8.0 %); Low-intermediate group, n = 63
(16.8 %); and Low-high group, n = 137 (36.5 %), and the
characteristics of the six groups are shown in Table 2.
Intravenous iron administration was not performed in
the three patients of High group, seven of Intermediate
group, six of Intermediate-high group, four of Low-
intermediate group, and three of Low-high group. All of
the other patients were administered with intravenous
iron less than 50 mg/week.There were 94 deaths (25.1 %) during the follow-up
period. The cause of death was CVD in 51 cases
(13.6 %), infection in 23 cases (6.1 %), cancer in 5 cases
(1.3 %), and gastrointestinal bleeding in 4 cases (1.1 %).
Of the 51 deaths due to CVD, 29 were due to congestive
heart failure, 8 were due to cerebrovascular accident in-
cluding intracranial hemorrhage, and 5 were due to
acute myocardial infarction; there were 4 cases of pulmon-
ary edema due to exogenous fluid, 2 cases of death due to
cardiac arrhythmia, and 3 cases of sudden death. We plot-
ted the all-cause and CVD-related mortality curves of the
six ERI variability groups by the Kaplan-Meier method
(Fig. 2a, b), and the all-cause and CVD-related mortality
rates were highest in the High ERI group. There was no
significant difference in all-cause mortality between EPO
group and DA group (Fig. 3, p = 0.7680). Moreover, there
was no significant difference between each ERI groups
and all-cause mortality in patients treated with EPO
(Fig. 4a, p = 0.3189). However, High group had sig-
nificantly higher mortality risk than those in the
other ERI groups in patients treated with DA (Fig. 4b,
p < 0.0001).
Figure 5 shows the unadjusted ORs for all-cause and
CVD-related mortality in each ERI variability group. The
risk for all-cause mortality in the High group was signifi-
cantly higher than those in the other groups (OR =
10.13, 95 % CI 3.56–32.07, p = 0.001). The High group
Table 2 Characteristics of the six groups for ERI variability
High Intermediate Low Intermediate-high Low-high Low-intermediate
(n = 31) (n = 68) (n = 46) (n = 30) (n = 137) (n = 63)
Male 45.2 % 73.5 % 78.3 % 63.3 % 58.4 % 68.3 %
Female 54.8 % 26.5 % 21.7 % 36.7 % 41.6 % 31.8 %
Age, years 75.1 ± 9.9 67.8 ± 12.9 60.5 ± 11.8 70.1 ± 13.3 66.6 ± 14.7 65.3 ± 12.3
BMI 19.7 ± 3.1 22.6 ± 3.3 23.9 ± 2.8 21.4 ± 3.9 21.4 ± 3.3 22.7 ± 3.6
HD vintage, months 62.9 ± 87.4 62.1 ± 68.1 70.6 ± 62.4 58.6 ± 59.2 65.1 ± 80.3 69.8 ± 81.8
Phosphorus, mg/dl 5.2 ± 1.6 5.3 ± 1.3 5.5 ± 1.3 5.0 ± 1.4 5.2 ± 1.2 5.3 ± 1.3
Calcium, mg/dl 8.5 ± 0.8 8.7 ± 0.8 8.8 ± 0.6 8.5 ± 0.6 8.7 ± 0.6 8.6 ± 0.8
Intact PTH, pg/ml 116.8 ± 87.5 138.4 ± 92.6 187.4 ± 267.7 167.3 ± 128.2 156.7 ± 191.0 140.7 ± 90.7
ALP, U/l 249.8 ± 137.2 234.0 ± 69.5 243.0 ± 121.0 225.1 ± 66.4 259.3 ± 109.9 236.8 ± 73.7
Ferritin, ng/ml 134.8 ± 101.8 78.8 ± 76.9 75.5 ± 63.9 71.1 ± 61.7 86.9 ± 94.8 104.1 ± 88.3
Hb, g/dl 9.7 ± 1.0 10.9 ± 0.9 11.4 ± 1.0 10.4 ± 1.0 10.8 ± 1.2 11.0 ± 0.8
Albumin, mg/dl 3.5 ± 0.4 3.6 ± 0.3 3.8 ± 0.3 3.6 ± 0.3 3.6 ± 0.4 3.7 ± 0.3
CRP, mg/dl 1.2 ± 1.7 0.5 ± 1.2 0.4 ± 0.9 0.5 ± 0.7 0.6 ± 1.8 0.6 ± 1.7
TSAT, % 20.8 ± 11.4 21.7 ± 10.1 23.7 ± 12.6 18.1 ± 9.0 21.5 ± 11.3 23.6 ± 12.4
Kt/V 1.5 ± 0.3 1.4 ± 0.2 1.4 ± 0.2 1.4 ± 0.3 1.4 ± 0.3 1.4 ± 0.3
Systolic BP, mmHg 150.7 ± 22.3 145.6 ± 26.0 147.3 ± 22.2 155.7 ± 19.1 150.6 ± 21.1 150.1 ± 23.1
Diastolic BP, mmHg 76.5 ± 12.1 76.4 ± 15.3 81.3 ± 13.4 80.1 ± 12.3 77.4 ± 13.7 78.4 ± 14.9
Shiohira et al. Renal Replacement Therapy  (2016) 2:10 Page 4 of 8was also significantly associated with CVD-related mor-
tality (OR = 3.67, 95 % CI 1.22–12.03, p = 0.003).
The results of the multivariate logistic regression
model adjusted for the age, sex, dialysis vintage, BMI,
the presence of diabetes, ferritin, albumin, CRP, phos-
phorus, and history of CVD showed that the High group
was at significantly higher risk for all-cause mortality
(OR = 3.63, 95 % CI 2.03–6.28, p < 0.0001; Table 3). For
CVD-related mortality, the High group had significantly
higher risk adjusted for the above variables except for
phosphorus (OR = 3.81, 95 % CI 1.68–8.04, p = 0.0019).
Older age, male, diabetes, and serum albumin levels
were independent predictors for all-cause mortality,
whereas only older age was an independent predictor for
CVD-related mortality.
Finally, we examined factors related to the High group.
The High group was associated with older age and had a
lower BMI, Hb and albumin, lower iron dosage, and a
higher ferritin and CRP levels (Table 4).
Discussion
The results of this study showed that the High group,
which had consistently high ERI values, was the highest
risk group for all-cause and CVD-related mortality in
Japanese HD patients compared with three amplitude
fluctuation groups. These findings were consistent with
the results of a previous study by Fujikawa et al. [10]
who showed that factoring out fluctuating ERI increases
the ability of consistently high ERI levels as an inde-
pendent risk factor for all-cause and CVD mortality of2104 HD patients in the Dialysis Outcomes and Practice
Patterns Study (DOPPS). Therefore, consistently high
ERI values in HD patients are a strong independent risk
factor for all-cause and CVD-related mortality.
The High group in our study was found to be associ-
ated with older age, female gender, low BMI, and low
serum albumin levels, and these findings are consistent
with the results of previous studies [3, 4, 11, 12]. How-
ever, CRP was not found to be associated with the High
group, although inflammatory conditions can elevate the
ERI by inducing the production of cytokines that sup-
press erythropoiesis [13–15]. This was probably because
the Low group, which had consistently low ERI values,
had an unexpectedly high CRP levels. Examination of
high CRP in the Low and High groups will provide an
information as to how factors affecting inflammation
elevate ERI. Schneider et al. [16] recently reported find-
ing that time-varying ESA resistance was associated with
higher rates of sudden death, infectious complications,
and all-cause mortality in the German Diabetes and Dia-
lysis study (4D study). The factors predicting ESA resist-
ance may be different from the study cohort.
The ERI values in the present study were lower than
in a previous study [4]. This is in part due to the fact
that ESA doses in Japan are lower than elsewhere [17],
and the low ERI values may predict a favorable outcome
in Japanese HD patients [18]. If higher ESA doses were
available in the Japanese healthcare system, HD patient
conditions causing high resistance to ESA might have
higher ERI values. ERI of a less limited range may be
Fig. 3 Comparison of mortality risk in patients treated with epoetin (EPO) and darbepoetin (DA)
a
b
Fig. 2 Kaplan-Meier survival curves of the six ERI variability groups. a All-cause. b CVD-associated
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ab
Fig. 4 Relationship between each ERI groups and all-cause mortality in patients treated with epoetin (EPO, a) and darbepoetin (DA, b)
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ERI variability should be performed to determine the
impact of the dose range. For a clinical understand-
ing of ERI, it would be beneficial to examine how
low ERI is affected by a limited range of ESA
dosing.Fig. 5 Odds ratio for all-cause and CVD-associated mortality of the six ERI vAccording to the literature, 90 % of renal anemia pa-
tients respond to EPO in a dose-dependent manner,
whereas the remaining 5–10 % of patients have either a
blunted or absent response to ESAs, despite high-dose
administration [19]. High ERI variability may be associ-
ated with hyporesponsiveness to ESA. Of the variousariability groups. a All-cause. b CVD-associated
Table 3 Independent factors associated with all-cause and CVD-related mortality in multivariate logistic regression analysis
All-cause mortality CVD-related mortality
HR 95 % CI p HR 95 % CI p
ERI variability groups (high vs. non-high) 3.64 2.03–6.28 <0.0001 3.81 1.68–8.04 0.0019
Age (years) 1.06 1.03–1.08 <0.0001 1.04 1.01–1.07 0.0090
Sex (female vs. male) 0.51 0.31–0.81 0.0042 0.57 0.29–1.07 0.0821
Dialysis vintage (month) 1.00 1.00–1.01 0.1158 1.00 0.99–1.00 0.3642
BMI >22 kg/m2 (yes vs. no) 1.15 0.73–1.80 0.5390 1.08 0.59–1.98 0.7986
Diabetes mellitus (yes vs. no) 1.60 1.03–2.47 0.0358 1.34 0.74–2.45 0.3333
History of CVD (yes vs. no) 1.21 0.57–2.29 0.5972 1.30 0.48–2.96 0.5763
Ferritin ≥100 ng/ml (yes vs. no) 1.43 0.93–2.18 0.1038 1.28 0.71–2.30 0.4052
Albumin ≥3.5 g/dl (yes vs. no) 0.47 0.29–0.76 0.0023 0.62 0.32–1.21 0.1567
CRP ≥1.0 mg/dl (yes vs. no) 0.68 0.37–1.20 0.1877 0.74 0.31–1.63 0.4686
Phosphorus ≥6 mg/dl (yes vs. no) 1.18 0.68–1.97 0.5407 1.14 0.54–2.23 0.7177
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deficiency is thought to be the most prevalent cause of
ESA hyporesponsiveness [20]. Intravenous iron adminis-
tration has been shown to improve ESA responsiveness,
leading to an increased Hb concentration and permitting
the use of a decreased ESA dose [21]. Kuragano et al.
have recently shown that iron administration was associ-
ated with an increased incidence for adverse events, in-
cluding CVD, infection, and hospitalization, among HDTable 4 Factors associated with high ERI variability
High (n = 31) Non-high (n = 345) p
Sex
Male 45.2 66.3
Female 54.8 33.7
Age, years 75.1 ± 9.9 66.1 ± 13.6 0.0003
BMI, kg/m2 19.7 ± 3.1 22.2 ± 3.5 0.0001
HD vintage, months 62.9 ± 87.4 65.6 ± 74.1 0.8531
Kt/V 1.5 ± 0.3 1.4 ± 0.3 0.1084
History of CVD 9.7 11.3 0.783
Systolic BP, mmHg 150.7 ± 22.3 149.5 ± 22.5 0.7784
Diastolic BP, mmHg 76.5 ± 12.1 78.2 ± 14.1 0.5215
Iron dosage, mg 585.8 ± 590.8 884.4 ± 689.0 0.0200
Laboratory data
Hb, g/dl 9.7 ± 1.0 10.9 ± 1.1 <0.0001
Ferritin, ng/ml 134.8 ± 101.8 85.6 ± 84.2 0.0023
Albumin, g/dl 3.5 ± 0.4 3.7 ± 0.3 0.0083
CRP, mg/dl 1.2 ± 1.7 0.6 ± 1.5 0.0281
Intact PTH, pg/ml 116.8 ± 87.5 155.2 ± 169.5 0.2213
Phosphorus, mg/dl 5.2 ± 1.6 5.3 ± 1.3 0.8339
Calcium, mg/dl 8.5 ± 0.8 8.7 ± 0.7 0.3027
ALP, U/l 249.8 ± 137.2 245.1 ± 95.7 0.8038
TSAT, % 20.8 ± 11.4 22.0 ± 11.3 0.5858patients who were treated with high doses of intravenous
iron compared with HD patients who were not treated
with iron [22]. In the present study, intravenous iron
was frequently administered to the high ERI group who
had the highest ferritin levels, suggesting the presence of
ESA hyporesponsiveness that is associated with an in-
creased mortality risk in high ERI group.
The present study had several limitations that were
mainly due to the observational nature of the study.
First, since this was a single-center cohort study, the
data and results may not be representative of HD pa-
tients in other countries, particularly because ESA doses
and Hb concentrations are generally lower in Japan than
in other countries. However, the mortality rate and other
baseline characteristics of our cohort were similar to those
of Japanese dialysis patients in general [23]. Second, the
longitudinal ERI assessments were based on data collected
at 2-month intervals. Since using different measurement
frequencies might make it possible to increase the prog-
nostic potential of ERI variability, the most appropriate
measurement frequencies and duration should be identi-
fied in subsequent investigations. Third, the average dose
of EPO in Japan is lower than in other countries because
of the healthcare expense reimbursement policy of the na-
tional health insurance system in Japan. Until April 2006,
the maximum dose of EPO was limited to 9000 U/week of
EPO alfa or EPO beta. Fourth, it is unknown why the pa-
tients treated with DA in High group had higher mortality
risk. ESA selection bias by nephrologists may be associ-
ated with the results. Moreover, DA might be adminis-
tered when response to EPO was insufficient for anemia
treatment.
Conclusions
The results of this study demonstrated that consistently
high ERI values in HD patients are an independent risk
factor for all-cause and CVD mortality. Further study
will be necessary to obtain a more detailed understand-
ing of the mechanisms that underlie the causal relation-
ship between ERI and mortality.
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